EBA
JAZZ icon

Eagle Bay Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Eagle Bay Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-125
Closed -$21.3K – 197
2025
Q4 		$21.3K Buy
+125
New +$19.2K 0.02% 249
2024
Q4 		– Sell
-35
Closed -$3.9K – 1023
2024
Q3 		$3.9K Hold
35
– – ﹤0.01% 1076
2024
Q2 		$3.74K Sell
35
-47
-57% -$5.17K ﹤0.01% 775
2024
Q1 		$9.87K Buy
+82
New +$10K 0.01% 587

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Eagle Bay Advisors's JAZZ Position: Q1 2026 in Review

Eagle Bay Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 125 shares — an estimated $21.3K sold.

Eagle Bay Advisors first reported a position in JAZZ in Q1 2024 and held it in 4 quarters. The position peaked at $21.3K in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Eagle Bay Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Eagle Bay Advisors sold 125 Jazz Pharmaceuticals shares in Q1 2026, an estimated $21.3K.
  • Eagle Bay Advisors first reported a position in Jazz Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Eagle Bay Advisors's Jazz Pharmaceuticals position peaked at $21.3K in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Eagle Bay Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.